Literature DB >> 15256830

Evaluation of GERD symptoms during therapy. Part II. Psychometric evaluation and validation of the new questionnaire ReQuest in erosive GERD.

H Mönnikes1, K D Bardhan, V Stanghellini, P Berghöfer, T D Bethke, D Armstrong.   

Abstract

BACKGROUND/AIMS: Evaluation of the response of gastroesophageal reflux disease (GERD) symptoms to treatment would be facilitated by a brief, valid, reliable and responsive, self-assessed GERD-sensitive scale. We therefore developed the Reflux Questionnaire (ReQuest). This publication describes the psychometric evaluation and validation of ReQuest.
METHODS: This second phase of development was based on data from a clinical trial of patients with erosive GERD who received pantoprazole 20 or 40 mg daily for 28 days and completed weekly the long, and daily the short version of ReQuest. The psychometric analyses of ReQuest included internal consistency, test-retest reliability and responsiveness. Construct validity was evaluated by comparison with the Gastrointestinal Symptom Rating Scale (GSRS) and the Psychological General Well-Being (PGWB) scale.
RESULTS: Validation of ReQuest indicated very high internal consistency (Cronbach's alpha = 0.90) and test-retest reliability (intraclass correlation coefficient 0.94 (long-long) and 0.86 (short-short)). This was also the case for the two subscales ReQuest-GI and ReQuest-WSO with Cronbach's alpha coefficients of 0.84 and 0.81. Responsiveness was high with a responsiveness index of >0.8 at day 28. Construct validity was good.
CONCLUSION: ReQuest is a highly reliable, valid and responsive self-assessment tool for evaluating treatment response in patients with erosive GERD, and can be applied daily.

Entities:  

Mesh:

Year:  2004        PMID: 15256830     DOI: 10.1159/000079708

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  10 in total

Review 1.  Development of an online library of patient-reported outcome measures in gastroenterology: the GI-PRO database.

Authors:  Puja Khanna; Nikhil Agarwal; Dinesh Khanna; Ron D Hays; Lin Chang; Roger Bolus; Gil Melmed; Cynthia B Whitman; Robert M Kaplan; Rikke Ogawa; Bradley Snyder; Brennan Mr Spiegel
Journal:  Am J Gastroenterol       Date:  2013-12-17       Impact factor: 10.864

Review 2.  Questionnaire based gastroesophageal reflux disease (GERD) assessment scales.

Authors:  V Pratap Mouli; Vineet Ahuja
Journal:  Indian J Gastroenterol       Date:  2011-07-23

3.  Influence of irritable bowel syndrome on treatment outcome in gastroesophageal reflux disease.

Authors:  Hubert Mönnikes; Robert C Heading; Holger Schmitt; Hubert Doerfler
Journal:  World J Gastroenterol       Date:  2011-07-21       Impact factor: 5.742

Review 4.  The concept of complete remission of gastro-oesophageal reflux disease : comparative efficacy of pantoprazole and esomeprazole using the ReQuest questionnaire.

Authors:  Alan B R Thomson
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

5.  The development of a new measure of quality of life in the management of gastro-oesophageal reflux disease: the Reflux questionnaire.

Authors:  Susan Macran; Samantha Wileman; Garry Barton; Ian Russell
Journal:  Qual Life Res       Date:  2006-10-11       Impact factor: 3.440

6.  Prediction of response to PPI therapy and factors influencing treatment outcome in patients with GORD: a prospective pragmatic trial using pantoprazole.

Authors:  Robert C Heading; Hubert Mönnikes; Anne Tholen; Holger Schmitt
Journal:  BMC Gastroenterol       Date:  2011-05-11       Impact factor: 3.067

7.  Physicians and patients measure different dimension on assessment for gastroesophageal reflux disease-related symptoms [corrected].

Authors:  Juan Carlos Lopez-Alvarenga; Sergio Sobrino-Cossio; Ronnie Fass; Jose A Vargas-Romero
Journal:  J Neurogastroenterol Motil       Date:  2011-10-31       Impact factor: 4.924

8.  Impact of PPIs on patient focused symptomatology in GERD.

Authors:  Abr Thomson
Journal:  Ther Clin Risk Manag       Date:  2008-12       Impact factor: 2.423

9.  Relief of Night-time Symptoms Associated With Gastroesophageal Reflux Disease Following 4 Weeks of Treatment With Pantoprazole Magnesium: The Mexican Gastroesophageal Reflux Disease Working Group.

Authors:  Juan Carlos López-Alvarenga; William Orr; José Antonio Vargas-Romero; José María Remes-Troche; Miguel Morales-Arámbula; Julio César Soto-Pérez; Gualberto Mateos-Pérez; Sergio Sobrino-Cossío; Oscar Teramoto-Matsubara; Aurelio López-Colombo; Antonio Orozco-Gamiz; Adolfo Saez-Ríos; Araceli Arellano-Plancarte; Jazmin Chiu-Ugalde; Anne Tholen; Silke Horbach; Lars Lundberg; Ronnie Fass
Journal:  J Neurogastroenterol Motil       Date:  2013-12-30       Impact factor: 4.924

10.  Factors influencing treatment outcome in patients with gastroesophageal reflux disease: outcome of a prospective pragmatic trial in Asian patients.

Authors:  Khean Lee Goh; Kee Don Choi; Myung-Gyu Choi; Tsai-Yuan Hsieh; Hwoon-Yong Jung; Han-Chung Lien; Jayaram Menon; Steven Mesenas; Hyojin Park; Bor-Shyang Sheu; Justin Cy Wu
Journal:  BMC Gastroenterol       Date:  2014-09-09       Impact factor: 3.067

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.